Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications.

Gougol A, Kwo P, Pike W, Farokhnia M, Hui G, Gombar S, Mirminachi B

Alimentary pharmacology & therapeutics11 Mar 2026Cited by 4 (Europe PMC)

PMID41813606DOI10.1111/apt.70596PepBankPUB-41813606

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with alcohol use disorder and metabolic dysfunction, pooled GLP-1RA therapy (semaglutide or tirzepatide) was associated with lower 1-year AUD relapse than AUD pharmacotherapy.
In plain wordsIn people with alcohol use disorder and metabolic problems, GLP-1 drugs as a group were linked to fewer relapses than usual alcohol medicines.
Peptide
Semaglutide
Outcome
Decrease1-year AUD relapse
Study
n: not reported in source
Comparator
FDA-approved AUD pharmacotherapies (naltrexone, acamprosate, disulfiram)
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Measurements
IRR
0.55 ratio
1-year AUD relapse, GLP-1RA vs AUD drugs
Source sentences
Summary
GLP-1RA therapy was associated with lower 1-year AUD relapse [IRR 0.55, 95% CI 0.42-0.73; p < 0.01]
1 context sentence(design, population, supporting numbers)
Summary · context
Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4181360601
02HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with alcohol use disorder and metabolic dysfunction, pooled GLP-1RA therapy (semaglutide or tirzepatide) was associated with lower 1-year AUD relapse than AUD pharmacotherapy.
In plain wordsIn people with alcohol use disorder and metabolic problems, GLP-1 drugs as a group were linked to fewer relapses than usual alcohol medicines.
Peptide
Tirzepatide
Outcome
Decrease1-year AUD relapse
Study
n: not reported in source
Comparator
FDA-approved AUD pharmacotherapies (naltrexone, acamprosate, disulfiram)
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Measurements
IRR
0.55 ratio
1-year AUD relapse, GLP-1RA vs AUD drugs
Source sentences
Summary
GLP-1RA therapy was associated with lower 1-year AUD relapse [IRR 0.55, 95% CI 0.42-0.73; p < 0.01]
1 context sentence(design, population, supporting numbers)
Summary · context
Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4181360602
03HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with alcohol use disorder and metabolic dysfunction, pooled GLP-1RA therapy (semaglutide or tirzepatide) was associated with greater BMI reduction than AUD pharmacotherapy.
In plain wordsIn people with alcohol use disorder and metabolic problems, GLP-1 drugs as a group were linked to a larger BMI drop than usual alcohol medicines.
Peptide
Semaglutide
Outcome
DecreaseBMI reduction
Study
n: not reported in source
Comparator
FDA-approved AUD pharmacotherapies (naltrexone, acamprosate, disulfiram)
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
greater BMI reduction (-1.3 vs. -0.3; p = 0.004
1 context sentence(design, population, supporting numbers)
Summary · context
Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4181360603
04HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with alcohol use disorder and metabolic dysfunction, pooled GLP-1RA therapy (semaglutide or tirzepatide) was associated with greater BMI reduction than AUD pharmacotherapy.
In plain wordsIn people with alcohol use disorder and metabolic problems, GLP-1 drugs as a group were linked to a larger BMI drop than usual alcohol medicines.
Peptide
Tirzepatide
Outcome
DecreaseBMI reduction
Study
n: not reported in source
Comparator
FDA-approved AUD pharmacotherapies (naltrexone, acamprosate, disulfiram)
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
greater BMI reduction (-1.3 vs. -0.3; p = 0.004
1 context sentence(design, population, supporting numbers)
Summary · context
Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4181360604
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with alcohol use disorder and metabolic dysfunction, pooled GLP-1RA therapy (semaglutide or tirzepatide) was associated with HbA1c improvement compared with AUD pharmacotherapy.
In plain wordsIn people with alcohol use disorder and metabolic problems, GLP-1 drugs as a group were linked to better blood sugar control than usual alcohol medicines.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Comparator
FDA-approved AUD pharmacotherapies (naltrexone, acamprosate, disulfiram)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
and HbA1c improvement (-1.0 vs. +0.1; p = 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4181360605
06HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with alcohol use disorder and metabolic dysfunction, pooled GLP-1RA therapy (semaglutide or tirzepatide) was associated with HbA1c improvement compared with AUD pharmacotherapy.
In plain wordsIn people with alcohol use disorder and metabolic problems, GLP-1 drugs as a group were linked to better blood sugar control than usual alcohol medicines.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Comparator
FDA-approved AUD pharmacotherapies (naltrexone, acamprosate, disulfiram)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
and HbA1c improvement (-1.0 vs. +0.1; p = 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4181360606
07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In patients with alcohol use disorder and metabolic dysfunction, decompensated cirrhosis trended lower with pooled GLP-1RA therapy, but the difference was not statistically significant.
In plain wordsIn people with alcohol use disorder and metabolic problems, serious liver disease trended lower with GLP-1 drugs as a group, but not significantly.
Peptide
Semaglutide
Outcome
No significant changeDecompensated cirrhosis incidence
Study
n: not reported in source
Comparator
FDA-approved AUD pharmacotherapies (naltrexone, acamprosate, disulfiram)
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
The incidence of decompensated cirrhosis trended lower but was not statistically significant [HR 0.52, p = 0.09].
1 context sentence(design, population, supporting numbers)
Summary · context
Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4181360607
08HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In patients with alcohol use disorder and metabolic dysfunction, decompensated cirrhosis trended lower with pooled GLP-1RA therapy, but the difference was not statistically significant.
In plain wordsIn people with alcohol use disorder and metabolic problems, serious liver disease trended lower with GLP-1 drugs as a group, but not significantly.
Peptide
Tirzepatide
Outcome
No significant changeDecompensated cirrhosis incidence
Study
n: not reported in source
Comparator
FDA-approved AUD pharmacotherapies (naltrexone, acamprosate, disulfiram)
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
The incidence of decompensated cirrhosis trended lower but was not statistically significant [HR 0.52, p = 0.09].
1 context sentence(design, population, supporting numbers)
Summary · context
Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4181360608
09HumanNot a test of Semaglutide aloneObservational studySafety outcome
In patients with alcohol use disorder and metabolic dysfunction, mortality was similar with pooled GLP-1RA therapy and AUD pharmacotherapy.
In plain wordsIn people with alcohol use disorder and metabolic problems, deaths were similar with GLP-1 drugs as a group and usual alcohol medicines.
Peptide
Semaglutide
Outcome
No significant changeMortality
Study
n: not reported in source
Comparator
FDA-approved AUD pharmacotherapies (naltrexone, acamprosate, disulfiram)
Outcome group
Mortality · Whole body
Source sentences
Summary
Mortality was similar.
1 context sentence(design, population, supporting numbers)
Summary · context
Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4181360609
10HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In patients with alcohol use disorder and metabolic dysfunction, mortality was similar with pooled GLP-1RA therapy and AUD pharmacotherapy.
In plain wordsIn people with alcohol use disorder and metabolic problems, deaths were similar with GLP-1 drugs as a group and usual alcohol medicines.
Peptide
Tirzepatide
Outcome
No significant changeMortality
Study
n: not reported in source
Comparator
FDA-approved AUD pharmacotherapies (naltrexone, acamprosate, disulfiram)
Outcome group
Mortality · Whole body
Source sentences
Summary
Mortality was similar.
1 context sentence(design, population, supporting numbers)
Summary · context
Exposure groups included ≥ 6 months of GLP-1RA therapy (semaglutide or tirzepatide) in comparison with FDA-approved pharmacotherapies for AUD.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4181360610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.